Janus Henderson Group
VYNE icon

Janus Henderson Group’s VYNE Therapeutics VYNE Stock Holding History

Janus Henderson Group’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-17,794
Closed -$5.94M – 1427
2019
Q4 		$5.94M Sell
17,794
-1,895
-10% -$632K ﹤0.01% 1026
2019
Q3 		$6.35M Sell
19,689
-435
-2% -$140K ﹤0.01% 1026
2019
Q2 		$8.68M Sell
20,124
-110
-0.5% -$54.4K ﹤0.01% 967
2019
Q1 		$11.4M Sell
20,234
-2,227
-10% -$1.07M 0.01% 896
2018
Q4 		$6.66M Sell
22,461
-5,808
-21% -$2.6M ﹤0.01% 937
2018
Q3 		$20M Sell
28,269
-10
-0% -$6.17K 0.01% 818
2018
Q2 		$16.5M Sell
28,279
-122
-0.4% -$94.8K 0.01% 843
2018
Q1 		$76.8M Buy
+28,401
New +$69.1M 0.05% 444

Other funds holding VYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group's VYNE Position: Q1 2020 in Review

Janus Henderson Group sold out of VYNE Therapeutics (VYNE) in Q1 2020, closing a stake of 17,794 shares — an estimated $5.94M sold.

Janus Henderson Group first reported a position in VYNE in Q1 2018 and held it in 8 quarters. The position peaked at $76.8M in Q1 2018. 93 funds tracked by Wall St. Rank hold VYNE as of Q1 2020.

  • Janus Henderson Group reported no remaining VYNE Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Janus Henderson Group sold 17,794 VYNE Therapeutics shares in Q1 2020, an estimated $5.94M.
  • Janus Henderson Group first reported a position in VYNE Therapeutics in Q1 2018 and held it in 8 quarters.
  • Janus Henderson Group's VYNE Therapeutics position peaked at $76.8M in Q1 2018.
  • 93 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2020.

Based on Janus Henderson Group's 13F filing for Q1 2020, filed 14 May 2020.